内镜手术对比调强放疗治疗可切除局部复发鼻咽癌:多中心开放标签随机对照3期试验
该多中心开放标签随机对照3期试验纳入200例既往放疗后可切除局部复发鼻咽癌患者,1:1随机接受内镜鼻咽切除术(ENPG)或调强放疗(IMRT)。ENPG组放疗相关晚期3级及以上不良事件及放疗特异性晚期毒性死亡均低于IMRT组。
要点
- ENPG组咽黏膜炎等3级及以上放疗相关晚期不良事件及放疗特异性晚期毒性死亡均低于IMRT组。
- ENPG可考虑作为该人群的标准治疗选择,但仍需长期随访确认疗效与毒性。
核心结论
- 在可切除局部复发鼻咽癌患者中,内镜手术较IMRT显著改善总生存,ENPG可考虑作为标准治疗选择。
研究设计与样本
- 多中心、开放标签、随机对照3期试验,在中国南方3家医院开展,200例患者1:1随机分配至ENPG组(n=100)或IMRT组(n=100),按治疗中心分层。
- 纳入18-70岁、Karnofsky体能状态评分≥70、病理诊断为未分化或分化型非角化性局部复发鼻咽癌且肿瘤局限于鼻咽腔、后鼻孔或鼻中隔、浅表咽旁间隙或蝶窦底壁的患者。
- 主要终点为3年总生存,疗效分析采用意向性治疗,安全性分析按实际接受的治疗进行。
主要发现
- 最常见的3级及以上放疗相关晚期不良事件为咽黏膜炎,ENPG组5例(5%,99例中) vs IMRT组26例(26%,101例中)。
- ENPG组5例(5%,99例中)和IMRT组20例(20%,101例中)死于放疗特异性晚期毒性,归因于既往放疗或试验放疗因放疗毒性长期性尚不明确。
临床怎么用
- 对于既往放疗后局限可切除的局部复发鼻咽癌患者,ENPG较IMRT显著改善3年总生存且放疗相关晚期毒性更低,可考虑作为标准治疗选择。
- 临床决策时需结合肿瘤可切除性评估(局限于鼻咽腔、后鼻孔或鼻中隔、浅表咽旁间隙或蝶窦底壁)及患者体能状态(KPS≥70)。
局限性
- 开放标签设计,治疗分组未设盲。
- 长期随访仍在进行,需进一步确定该策略的远期疗效与毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of surgery compared with reirradiation in the primary treatment of patients with resectable, locally recurrent nasopharyngeal carcinoma (NPC) who have previously received radiotherapy is a matter of debate. In this trial, we compared the efficacy and safety outcomes of salvage endoscopic surgery versus intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent NPC. METHODS: This multicentre, open-label, randomised, controlled, phase 3 trial was done in three hospitals in southern China. We included patients aged 18-70 years with a Karnofsky Performance Status score of at least 70 who were histopathologically diagnosed with undifferentiated or differentiated, non-keratinising, locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus. Eligible patients were randomly assigned (1:1) to receive either endoscopic nasopharyngectomy (ENPG group) or IMRT (IMRT group). Randomisation was done manually using a computer-generated random number code and patients were stratified by treatment centre. Treatment group assignment was not masked. The primary endpoint was overall survival, compared between the groups at 3 years. Efficacy analyses were done by intention to treat. Safety analysis was done in patients who received treatment according to the treatment they actually received. This trial was prospectively registered at the Chinese Clinical Trial Registry, ChiCTR-TRC-11001573, and is currently in follow-up. FINDINGS: Between Sept 30, 2011, and Jan 16, 2017, 200 eligible patients were randomly assigned to receive either ENPG (n=100) or IMRT (n=100). At a median follow-up of 56·0 months (IQR 42·0-69·0), 74 patients had died (29 [29%] of 100 patients in the ENPG group and 45 [45%] of 100 patients in the IMRT group). The 3-year overall survival was 85·8% (95% CI 78·9-92·7) in the ENPG group and 68·0% (58·6-77·4) in the IMRT group (hazard ratio 0·47, 95% CI 0·29-0·76; p=0·0015). The most common grade 3 or worse radiation-related late adverse event was pharyngeal mucositis (in five [5%] of 99 patients who underwent ENPG and 26 [26%] of 101 patients who underwent IMRT). Five [5%] of the 99 patients who underwent ENPG and 20 [20%] of the 101 patients who underwent IMRT died due to late toxic effects specific to radiotherapy; attribution to previous radiotherapy or trial radiotherapy is unclear due to the long-term nature of radiation-related toxicity. INTERPRETATION: Endoscopic surgery significantly improved overall survival compared with IMRT in patients with resectable locally recurrent NPC. These results suggest that ENPG could be considered as the standard treatment option for this patient population, although long-term follow-up is needed to further determine the efficacy and toxicity of this strategy. FUNDING: Sun Yat-sen University Clinical Research 5010 Program.
引用
- Liu YP, Wen YH, Tang J, et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021. PMID: 33600761. doi:10.1016/S1470-2045(20)30673-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。